ROME Trial Shows Dual Tissue and Liquid Biopsy Approach Improves Survival in Advanced Solid Tumor Patients

A recent clinical trial investigated the effectiveness of using both tissue and liquid biopsies to personalize cancer treatment for patients with advanced solid tumors. The ROME phase 2 trial examined whether this dual-biopsy approach improved survival rates compared to standard treatment methods or relying on a single biopsy. The ROME trial demonstrated that treatment strategies guided by the combined analysis of tissue and liquid biopsies led to improved survival outcomes in patients with advanced solid tumors. The study compared these outcomes against those achieved with standard of care treatments and strategies based on single-biopsy analysis. The results suggest the potential benefit of incorporating dual profiling into precision oncology practices.

Newsflash | Powered by GeneOnline AI
Date: April 29, 2025

Related posts:

Study Links Prior COVID-19 in Children to Subsequent Kidney, Gastrointestinal, and Cardiovascular Issues Presidential Order Could Alter Medical School Accreditation Standards and Curriculum Requirements. American Lung Association Campaign Focuses on Updated Pneumococcal Vaccine Schedules to Protect High-Risk Groups Aviva Capital Partners and Socius Invest £1 Billion in New Cancer Research and Treatment Center in Sutton, London

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後